Streetbeat News

NVCT

Nuvectis Pharma, Inc.

https://www.nuvectis.com

Industry

Biotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Open

8.23

Mkt cap

156M

Volume

303K

High

8.85

P/E Ratio

-6.47

52-wk high

12.10

Low

8.02

Div yield

N/A

52-wk low

5.85

Wall Street analysts predict a significant upside potential of 169.94% for Nuvectis Pharma (NVCT), driven by upward trends in earnings estimate revisions.

Portfolio Pulse from

November 07, 2024 | 4:15 pm

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has released its third quarter 2024 financial results and business highlights, focusing on its progress in developing precision medicines for oncology.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

A new report highlights the potential of Nuvectis Pharma's NXP900 in non-small cell lung cancer (NSCLC) and anticipates upcoming data on NXP800. This positions Nuvectis among precision oncology leaders like Nuvalent and Summit Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 3:51 pm

Nuvectis Pharma, Inc. (NASDAQ:NVCT) will present its NXP900 at the 2024 AACR-NCI-EORTC Symposium, highlighting its focus on innovative cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:06 pm

In Wednesday's after-market session, several health care stocks experienced significant price movements. Molecular Templates (MTEM) saw a remarkable increase of 189.2%, while HCW Biologics (HCWB) experienced a notable decline of 14.8%. Other gainers included Klotho Neurosciences (KLTO) and Chromocell Therapeutics (CHRO), while Biodexa Pharmaceuticals (BDRX) and Capricor Therapeutics (CAPR) were among the losers.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 8:31 pm

Nuvectis Pharma has received Orphan Drug Designation from the FDA for its drug NXP800, aimed at treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation could provide benefits such as market exclusivity and tax credits.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:02 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Nuvectis Pharma (NASDAQ:NVCT) and maintained a $21 price target.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:42 pm

Nuvectis Pharma (NASDAQ:NVCT) reported Q2 losses of $(0.26) per share, meeting analyst expectations and showing a 31.58% improvement from the $(0.38) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:44 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Nuvectis Pharma (NASDAQ:NVCT) with a maintained price target of $21.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 7:03 pm

Nuvectis Pharma (NASDAQ:NVCT) reported Q1 earnings with losses of $(0.25) per share, surpassing the analyst consensus estimate of $(0.40) by 37.5%. This represents a 7.41% improvement over the previous year's losses of $(0.27) per share.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.